NASDAQ:PEPG PepGen Q3 2026 Earnings Date & Estimates $2.60 +0.07 (+2.77%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$2.59 -0.01 (-0.38%) As of 10/16/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. PepGen is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call DateNovember 12, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from PepGen in Q3 2026PepGen is expected to post earnings of -$0.27 per share. In the same quarter a year earlier PepGen reported -$0.52 per share. PepGen last reported on August 6, 2026, posting -$0.26 per share and beating the -$0.2845 consensus estimate. PepGen has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.27Prior-Year EPS-$0.52Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.26 (Beat by +$0.0245)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report PepGen Q3 2026 Earnings FAQ When does PepGen report Q3 2026 earnings? PepGen (NASDAQ:PEPG) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is PepGen's Q3 2026 earnings call? PepGen's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for PepGen? Analysts expect PepGen to post earnings of -$0.27 per share for Q3 2026. PepGen Earnings HeadlinesPepGen (NASDAQ:PEPG) Stock Gets Downgrade from Wall Street ZenOctober 10, 2026 | americanbankingnews.comPepGen Inc. (PEPG) Interactive Stock Chart - Yahoo FinanceSeptember 16, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 studyAugust 7, 2026 | msn.comPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewAugust 6, 2026 | businesswire.comPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsAugust 6, 2026 | businesswire.comSee More PepGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email. Email Address About PepGenPepGen (NASDAQ:PEPG) Inc. is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins. PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues. The platform is intended to support treatments that can alter RNA processing, including exon skipping and other gene-regulating approaches. The company’s lead program, PGN-EDO51, is being developed for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. PepGen is also advancing programs for other neuromuscular disorders, including myotonic dystrophy type 1. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen’s research and development activities are focused primarily on rare genetic diseases, with CEO James McArthur among its leadership team.View PepGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
